host top manag meet yesterday appear posit
growth key hematolog immunolog portfolio potenti support
strateg acquisit might involv new therapeut area stock appear
reflect risk opportun view current share price buy opportun
assum success hematolog immunolog franchis tandem
modest success franchis manag believ deliv growth
humira biosimilar competit global ex experienc biosimilar
competit across busi price aggress
first assum yet deliv growth driven new product humira
foreign market includ australia brazil canada japan patent protect
humira loss exclus first biosimilar could launch
januari much larger obstacl also much time establish
grow new product provid off-set investor apprehens transit
like linger lessen new product regulatori commerci mileston
achiev expect year new product establish
market leverag driven humira formulari posit roughli
manag provid addit color strategi maintain growth
humira patent/exclus expir upadacitinib file ra
risankizumab file psoriasi view ideal candid replace/
improv upon specif indic humira clinic profil
demonstr superior humira certain indic potenti add new
indic humira atop dermat initi approv
manag indic next step upadacitinib risankizumab
obtain commerci manag care access least educ physician
rel prescrib new drug estim take month initi ramp
upadacitinib risankizumab could measur acceler access
educ place activ posit new agent ahead
humira revenu impact expect least off-set potenti exceed lost
humira sale indic possibl humira sale could peak earlier
expect transit step upadacitinib risankizumab gain traction
quickli establish manag note oper margin
two agent rang despit royalti paid bi risankizumab peg
peak sale upadacitinib forecast sale peak sale
rizankizumab forecast sale
risankizumab expect approv psoriasi compani
anticip fda adcom would notifi one request
regulatori discuss proceed well upadacitinib ra expect
approv soon know fda adcom requir nme ra
often garner panel pursu dose ra although file submiss
contain result compani indic major
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani pipelin promis
agent opportun upward revis sever front stock
attract valu versu group overal attribut argu purchas
upadacitinib approv ra
risankizumab approv psoriasi
humira sale trend particularli
orilissa uptak endometriosi uterin
humira sale
humira biosimilar eros less
especi oncolog immunolog
 bolster long-term visibl
humira erod quickli
expect eu and/or launch
oncolog immunolog product
global biopharmaceut compani product use treat rheumatoid
arthriti psoriasi crohn ulcer coliti hcv hematolog tumor among other
humira ra crohn domin product repres total sale
profit also pipelin compound indic phase ii
phase develop
pk/pd benefit deriv dose howev like
different/high dose indic atop dermat crohn etc
provid addit sourc growth humira biosimilar pressur
creat strong portfolio hematolog imbruvica venclexta gener
revenu project two asset grow hematolog
franchis achiev sale peak forecast imbruvica
revenu peg peak sale
forecast venclexta sale peg peak
sale venclexta share asset roch
imbruvica cll new patient market share current manag
believ grow greater use catalyz strong data phase
illumin result imbruvica gazyva present
subsequ label expans longer durat therapi low singl digit market
growth estim total cll patient imbruvica
inclus estim obtain market share cll
venclexta make headway cll aml mm data come
emphas make solid progress advanc venclexta cll
strong data rituximab phase murano gazyva phase
addit begin evalu combin venclexta
imbruvica /- gazyva three new phase trial glow initi april
other yet initi largest near-term opportun cll imbruvica
transit cll combin venclexta imbruvica cll
long-term readout
novemb venclexta receiv acceler condit approv newly-
diagnos aml elderli patient combin hypomethyl agent
azacitidin low dose cytarabin ldac venclexta treatment aml aim
provid much-need treatment option roughli aml patient
undergo intens chemotherapi high-dos induct stem cell transplant
approv base impress data phase i/ii phase ib
venclexta combin demonstr orr histor
compar approv subject confirm phase viale-a combin
azacitidin elderly-nav aml patient phase viale-c combin low
dose cytarabin treatment-nav adult patient year old data
confirmatori phase studi expect
strong activ early-stag studi bellini trial venclexta
bortezomib proteasom inhibitor takeda dexamethason mm first
opportun determin regimen perform phase decemb
phase ii result demonstr combin venclexta carfilzomib
proteasom inhibitor dexamethason achiev orr median
time treatment month carfilzomib consid superior bortezomib
refractori patient respons rate could less robust bellini nonetheless
manag believ would solid outcom bellini
replic earli data venclexta would vie posit market regard
time manag comment event-driven trial previous
anticip data
manag indic comfort current pipelin look
way strengthen core area build new vertic expertis
particular addit late stage product could bolster
time-frame would high interest specif area interest solid tumors/broad
oncolog cystic fibrosi and/or virolog interest larg
abbv prioriti capit deploy continu reinvest busi
dividend payment commit grow dividend long-term
share buy-back abbv gross debt doesnt imped busi
deliv good growth gener cash per year
updat model post result meet manag sale
ep reduc mainli due lower humira estim eu reflect
aggress biosimilar price tactic ep intact vs
guidanc sale consist guidanc
ep estim clip sale reduc
ep peg decreas sale
reduc ep compound-annual-growth-rate remain although
growth rate clip still forecast ep declin
howev manag believ grow throughout time
mani opportun upsid particularli new product and/or bd
compani data cowen compani
compani data cowen compani
ww foreign lc ex foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww ip expect hold till post settlement sever other launch later humira biosimilar launch eu declin year expect foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid steadi sale gener difficult formul synthroid levothyroxin overact thyroidlupron leuprolid line extens support foreign lc ex leuprolid gener avail lupron still lead market mo depotsynagi foreign lc ex human mab bind f-protein rsvdepakot divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launch franchiseandrogel testosteron gel hypergonad market declin gener pressurekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust assum ceas humira patent us includ nimbex vicodin etc emerg mkt growth foreign lc ex cowen
compani data cowen compani
 combin glecaprevir pi pibrentasvir inhibitor hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex approv cll delet r/r cll rituxanvenclexta venetoclax select inhibitor cllorilissa- oral gnrh antagonist partial estrogen suppress endometriosi approv uterin fibroib file partnership neurocrin eign lc ex similar lupron zoladexelagolix hold ww right orilissa gnrh antagonistsrova-t meru sclc mainten complet stop futil eign lc ex stem cell technolog solid tumor target peak salesrova-t stemcentrx acq conting payment close guidanc file june psoriasi ph crohn uc ph ii eign lc ex month bi bi receiv mileston royaltiesduodopa infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson supadacitinib- guidanc ra file ph atop dermat ph ii axspa gca eign lc ex jak inhibitor competit profil ra crohn uc ad cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl myeloma r/r mm foreign lc ex trial fail glioblastoma filingveliparib bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase zinbryta foreign lc ex fx zinbryta daclizumab withdrawn global march foreign lc ex foreign lc ex guidanc annual revenu growth cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
